Abstract. Bladder cancer screening has been perplexing the uro-oncological community for the last decade. In this commentary, we ruminate on the feasibility of bladder cancer screening in our population based on epidemiological proponents.
tubules in the kidney. NAT1*14A has been reported to produce a slow acetylation phenotype; thus has been linked to increasing risk of bladder cancer. The frequency of NAT1*14A has been reported to be the highest in Lebanese people compared to other ethnicities [6] . Yassine et al. conducted an elegant case-control study to assess the effects of NAT1 genetic polymorphism on bladder cancer risk among Lebanese men. The authors found that patients with bladder cancer have significantly higher clustering of NAT1*14A compared to control [7] .
Screening for breast cancer, colon cancer and, more recently, lung cancer has gained acceptance. However, screening for bladder cancer has not been adopted yet. This is partly due to the lack of diseasespecific symptoms. Adding to that, a large number of bladder cancer cases has an indolent course.
There are a scant number of studies that have been conducted reporting on the screening of bladder cancer. All these studies have screened populations with high-risk factors for developing bladder cancer.
Madeb et al. reported on the usefulness of using home urine dipstick as a screening test in detecting bladder cancer at an earlier stage and improving the survival outcome of the screened population [8] . In addition to the urine dipstick and urine cytology, another group incorporated urine biomarkers (NMP22, Urovysion) to improve the sensitivity of bladder tumor detection. The authors concluded that using this panel test as a screening tool for patients with a history of smoking of ≥40 pack-years enabled detection of malignancy in 3.3% of this population [9] .
The ideal screening test should be safe, cheap, non-invasive, and cost-effective. However, the gold standard test to diagnose bladder cancer is cystoscopy; which is not practical to screen asymptomatic individuals because of the invasive nature of the procedure and related expenses. On the other hand, there are a plethora of molecular markers that have been developed in the last decade (NMP22, BTA, Survivin, BLCA-4, DD23, uCyt+, UroVysion), all these markers have been studied extensively in disease diagnosis among symptomatic patients, or have been part of the surveillance of bladder cancer patients. Unfortunately, none of these markers is available in Lebanon.
It is very hard to draw a conclusion on the utility of any of these markers in screening from the available literature, because the performance of these markers depends on disease prevalence in the population.
Lotan et al. using Markov model to estimate cumulative cancer-related costs and the efficacy of screening of a high-risk population for bladder cancer, demonstrated an improvement in the overall survival in addition to cost saving if the cancer incidence is >1.6% [10] .
In summary, there is emerging evidence of the benefit of bladder cancer screening in highly selected populations. However, these studies were conducted in developed countries with low incidence of bladder cancer, and this may play a major role in disparaging the value of bladder cancer screening program. Amid the debate of the importance of bladder cancer screening, it is a praiseworthy argument that screening of our population might show unparalleled results contingent upon the high figure of disease occurrence in Lebanon.
